Showing 1 - 4 of 4 Myasthenia Gravis

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG). NCT number: NCT03971422 ... Read more >

Status: Open Not Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG). ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >

Status: Open Not Enrolling

Investigator: Ericka Greene

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >